Subchronic exposure to titanium dioxide nanoparticles modifies cardiac structure and performance in spontaneously hypertensive rats.
Arrhythmias
Cardiac electrophysiology
Cardiac fibrosis
Nanotoxicology
Titanium dioxide nanoparticles
Journal
Particle and fibre toxicology
ISSN: 1743-8977
Titre abrégé: Part Fibre Toxicol
Pays: England
ID NLM: 101236354
Informations de publication
Date de publication:
24 06 2019
24 06 2019
Historique:
received:
03
12
2018
accepted:
06
06
2019
entrez:
26
6
2019
pubmed:
27
6
2019
medline:
25
2
2020
Statut:
epublish
Résumé
Non-communicable diseases, intended as the results of a combination of inherited, environmental and biological factors, kill 40 million people each year, equivalent to roughly 70% of all premature deaths globally. The possibility that manufactured nanoparticles (NPs) may affect cardiac performance, has led to recognize NPs-exposure not only as a major Public Health concern, but also as an occupational hazard. In volunteers, NPs-exposure is problematic to quantify. We recently found that inhaled titanium dioxide NPs, one of the most produced engineered nanomaterials, acutely increased cardiac excitability and promoted arrhythmogenesis in normotensive rats by a direct interaction with cardiac cells. We hypothesized that such scenario can be exacerbated by latent cardiovascular disorders such as hypertension. We monitored cardiac electromechanical performance in spontaneously hypertensive rats (SHRs) exposed to titanium dioxide NPs for 6 weeks using a combination of cardiac functional measurements associated with toxicological, immunological, physical and genetic assays. Longitudinal radio-telemetry ECG recordings and multiple-lead epicardial potential mapping revealed that atrial activation times significantly increased as well as proneness to arrhythmia. At the third week of nanoparticles administration, the lung and cardiac tissue encountered a maladaptive irreversible structural remodelling starting with increased pro-inflammatory cytokines levels and lipid peroxidation, resulting in upregulation of the main pro-fibrotic cardiac genes. At the end of the exposure, the majority of spontaneous arrhythmic events terminated, while cardiac hemodynamic deteriorated and a significant accumulation of fibrotic tissue occurred as compared to control untreated SHRs. Titanium dioxide nanoparticles were quantified in the heart tissue although without definite accumulation as revealed by particle-induced X-ray emission and ultrastructural analysis. The co-morbidity of hypertension and inhaled nanoparticles induces irreversible hemodynamic impairment associated with cardiac structural damage potentially leading to heart failure. The time-dependence of exposure indicates a non-return point that needs to be taken into account in hypertensive subjects daily exposed to nanoparticles.
Sections du résumé
BACKGROUND
Non-communicable diseases, intended as the results of a combination of inherited, environmental and biological factors, kill 40 million people each year, equivalent to roughly 70% of all premature deaths globally. The possibility that manufactured nanoparticles (NPs) may affect cardiac performance, has led to recognize NPs-exposure not only as a major Public Health concern, but also as an occupational hazard. In volunteers, NPs-exposure is problematic to quantify. We recently found that inhaled titanium dioxide NPs, one of the most produced engineered nanomaterials, acutely increased cardiac excitability and promoted arrhythmogenesis in normotensive rats by a direct interaction with cardiac cells. We hypothesized that such scenario can be exacerbated by latent cardiovascular disorders such as hypertension.
RESULTS
We monitored cardiac electromechanical performance in spontaneously hypertensive rats (SHRs) exposed to titanium dioxide NPs for 6 weeks using a combination of cardiac functional measurements associated with toxicological, immunological, physical and genetic assays. Longitudinal radio-telemetry ECG recordings and multiple-lead epicardial potential mapping revealed that atrial activation times significantly increased as well as proneness to arrhythmia. At the third week of nanoparticles administration, the lung and cardiac tissue encountered a maladaptive irreversible structural remodelling starting with increased pro-inflammatory cytokines levels and lipid peroxidation, resulting in upregulation of the main pro-fibrotic cardiac genes. At the end of the exposure, the majority of spontaneous arrhythmic events terminated, while cardiac hemodynamic deteriorated and a significant accumulation of fibrotic tissue occurred as compared to control untreated SHRs. Titanium dioxide nanoparticles were quantified in the heart tissue although without definite accumulation as revealed by particle-induced X-ray emission and ultrastructural analysis.
CONCLUSIONS
The co-morbidity of hypertension and inhaled nanoparticles induces irreversible hemodynamic impairment associated with cardiac structural damage potentially leading to heart failure. The time-dependence of exposure indicates a non-return point that needs to be taken into account in hypertensive subjects daily exposed to nanoparticles.
Identifiants
pubmed: 31234877
doi: 10.1186/s12989-019-0311-7
pii: 10.1186/s12989-019-0311-7
pmc: PMC6591966
doi:
Substances chimiques
titanium dioxide
15FIX9V2JP
Titanium
D1JT611TNE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
25Références
Part Fibre Toxicol. 2017 Nov 25;14(1):47
pubmed: 29178961
Am J Cardiol. 1969 Apr;23(4):528-37
pubmed: 5781880
J Occup Environ Med. 2012 Nov;54(11):1389-94
pubmed: 23059552
Circulation. 1996 Mar 1;93(5):1043-65
pubmed: 8598068
Hypertension. 2017 Jun;69(6):1092-1103
pubmed: 28373589
Part Fibre Toxicol. 2013 Apr 15;10:15
pubmed: 23587290
Nanotoxicology. 2015;9(8):941-51
pubmed: 25475392
Environ Health Perspect. 2011 Feb;119(2):176-81
pubmed: 20864429
Public Health Action. 2015 Sep 21;5(3):156-7
pubmed: 26393110
Am J Physiol Heart Circ Physiol. 2014 Aug 15;307(4):H467-76
pubmed: 24929855
Inhal Toxicol. 2013 Dec;25(14):802-12
pubmed: 24304307
Nanomedicine (Lond). 2013 May;8(5):725-737
pubmed: 23140503
Molecules. 2018 Aug 06;23(8):
pubmed: 30082584
Part Fibre Toxicol. 2014 Dec 09;11:63
pubmed: 25487314
Environ Health Perspect. 2001 Aug;109 Suppl 4:547-51
pubmed: 11544161
Environ Health Perspect. 2002 Aug;110(8):749-55
pubmed: 12153754
Can J Cardiol. 2006 May 15;22(7):553-5
pubmed: 16755308
Nanotoxicology. 2017 May;11(4):454-464
pubmed: 28290735
Nanoscale Res Lett. 2015 Dec;10(1):1029
pubmed: 26269254
Sci Transl Med. 2018 Jan 17;10(424):
pubmed: 29343624
Physiol Behav. 1996 Dec;60(6):1397-401
pubmed: 8946481
Toxicol In Vitro. 2015 Apr;29(3):426-37
pubmed: 25526690
Toxicol Appl Pharmacol. 2000 May 1;164(3):250-63
pubmed: 10799335
Part Fibre Toxicol. 2008 Dec 01;5:17
pubmed: 19046442
Nanotoxicology. 2012 May;6(3):263-71
pubmed: 21504370
Environ Sci Pollut Res Int. 2019 May;26(13):12648-12661
pubmed: 30903465
Exp Physiol. 2006 May;91(3):571-80
pubmed: 16452123
ACS Nano. 2017 May 23;11(5):4542-4552
pubmed: 28443337
Nanotoxicology. 2015;9(8):1013-22
pubmed: 25993494
Pavlov J Biol Sci. 1978 Oct-Dec;13(4):211-6
pubmed: 748844
Fibrogenesis Tissue Repair. 2012 Sep 03;5(1):15
pubmed: 22943504
PLoS One. 2014 Nov 14;9(11):e112697
pubmed: 25398004
Toxicol Sci. 2000 Apr;54(2):441-51
pubmed: 10774827
Toxicol Lett. 2007 Jul 10;171(3):126-37
pubmed: 17606336
Circ Res. 2006 Mar 31;98(6):801-10
pubmed: 16484613
J Occup Health. 2016 Nov 29;58(6):602-611
pubmed: 27725490
Food Chem Toxicol. 2013 Aug;58:280-8
pubmed: 23665316
Am J Physiol Heart Circ Physiol. 2006 Nov;291(5):H2192-8
pubmed: 16766638
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Toxicol Appl Pharmacol. 2012 Oct 15;264(2):232-45
pubmed: 22981607
Toxicol Sci. 2003 Feb;71(2):237-45
pubmed: 12563109
Curr Heart Fail Rep. 2017 Aug;14(4):235-250
pubmed: 28707261
F1000Res. 2016 Feb 22;5:
pubmed: 26962445
Toxicology. 2017 Jun 1;384:59-68
pubmed: 28450064
Int J Mol Sci. 2017 Dec 19;18(12):
pubmed: 29257061
Environ Health Perspect. 2007 Mar;115(3):397-402
pubmed: 17431489
Toxicology. 2007 Jan 25;230(1):90-104
pubmed: 17196727
Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2336-47
pubmed: 18849337
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
Gastroenterol Hepatol Bed Bench. 2018 Spring;11(2):159-168
pubmed: 29910858
Nanotoxicology. 2014 Jun;8(4):447-54
pubmed: 23593933